EQ 500 500mg/ml 10ml Vial by Dragon-Pharma

Usage

1. Confirm ester selection rationale before starting: EQ 500 uses the undecylenate ester, which provides a longer release window than boldenone cypionate; if your cycle requires rapid plasma saturation, plan a loading protocol during weeks 1–2 accordingly.
2. Calculate your exact weekly volume: divide your target weekly dose (mg) by 500 to determine millilitres required — e.g., 600 mg ÷ 500 mg/ml = 1.2 ml/week.
3. Draw the calculated volume using a 21–23 gauge needle for withdrawal from the multi-dose vial, then switch to a 23–25 gauge needle for intramuscular injection to minimise injection-site trauma.
4. Select the injection site appropriate for the volume: gluteus maximus accommodates up to 3 ml per site; for the typical 1.0–1.6 ml doses achievable with EQ 500, the vastus lateralis is also suitable.
5. Apply strict aseptic technique on every draw: wipe the vial stopper with a 70 % isopropyl alcohol swab and allow to dry before each needle insertion to preserve multi-dose sterility.
6. Store the opened vial upright at room temperature (15–25 °C), away from direct light; do not refrigerate the oil-based solution as cooling increases viscosity and complicates accurate drawing.

Warnings

Frequently asked questions

How does boldenone undecylenate differ from boldenone cypionate in terms of ester length and dosing frequency?

Boldenone undecylenate carries an eleven-carbon fatty acid chain, producing a longer hydrolysis window than boldenone cypionate, which uses an eight-carbon chain. In practice, undecylenate supports once- or twice-weekly injection schedules, while cypionate requires more frequent administration to maintain comparable plasma consistency. EQ 500's undecylenate formulation is therefore better suited to 12–16 week cycles where injection frequency is a practical consideration.

Why does the form of administration matter when choosing a boldenone product — injectable oil versus other delivery routes?

Esterified boldenone is only pharmacologically active via intramuscular injection; oral administration of the esterified form results in near-total first-pass hepatic degradation before the compound reaches systemic circulation. The oil-based injectable form used in EQ 500 allows the undecylenate ester to be cleaved slowly at the injection depot, releasing free boldenone into the bloodstream over an extended period. No practical oral boldenone undecylenate formulation exists for performance use.

Which boldenone ester is better suited to shorter cycles — undecylenate or a shorter-chain alternative?

Shorter-chain esters such as boldenone acetate reach peak plasma levels faster, making them theoretically preferable for cycles under eight weeks — but they require daily injections. Boldenone undecylenate, as used in EQ 500, takes several weeks to accumulate to steady-state plasma levels, making it best suited to cycles of at least twelve weeks. For a short cycle, the undecylenate ester's slow saturation kinetics are a disadvantage compared with cypionate or acetate variants.

What is the practical injection volume advantage of EQ 500's 500 mg/ml concentration compared with standard boldenone preparations?

At 500 mg/ml, a 500 mg weekly dose requires exactly 1 ml; the same dose from a 200 mg/ml preparation requires 2.5 ml, and from a 250 mg/ml product requires 2.0 ml. For users targeting 700–800 mg/week, EQ 500 delivers that dose in 1.4–1.6 ml total — a volume comfortably administered in a single gluteal injection. This concentration advantage directly reduces injection-site discomfort and the number of injection sites required per week.

How should a 10 ml multi-dose vial of EQ 500 be stored after the first draw to maintain sterility and potency?

After the first puncture, EQ 500 should be stored upright at 15–25 °C, away from direct light and heat sources. Refrigeration is not recommended because cooling thickens the oil carrier, making accurate dosing with a syringe more difficult. The rubber stopper should be cleaned with a 70 % isopropyl alcohol swab before every draw. When handled with proper aseptic technique, a multi-dose vial maintains sterility for the duration of its use within a single cycle. (2) angle_used

Manufacturer

Dragon-Pharma's quality assurance framework for EQ 500 is structured around two distinct analytical gates applied sequentially at the batch level: a high-performance liquid chromatography (HPLC) potency assay and a Limulus Amebocyte Lysate (LAL) endotoxin test. The HPLC stage confirms that finished boldenone undecylenate concentration in each vial falls within specification of the declared 500 mg/ml value — a measurement taken at the completed product rather than at the raw API receipt stage alone. The LAL endotoxin test is applied separately to verify that the injectable oil solution meets the microbial contamination thresholds required for intramuscular preparations. Results from both tests are archived at the lot number level, meaning a specific batch of EQ 500 carries traceable analytical documentation rather than a generalised product-level quality claim. This dual-checkpoint model — potency confirmed by HPLC, sterility confirmed by LAL — reflects Dragon-Pharma's established position as a brand whose testing infrastructure is operationally integrated into every production run, not applied selectively or on a sampled basis.